Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Tatsuji Mino, Yuta Katayama, MD PhD, Tatsuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Takeshi Okatani, MD, Ryota Imanaka, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Shinya Katsutani, MD PhD, Tsuyoshi Muta, MD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2018-99-113461

Published: 2018

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Kenshi Suzuki, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD, Yoshiaki Kuroda, MD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Shimizu Kazuyuki, MD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4436.

https://doi.org/10.1182/blood.V128.22.4436.4436

Published: 2016

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Hirokazu Murakami, MD, Kenshi Suzuki, Naoki Takezako, MD PhD, Jun Konishi, Kazutaka Sunami, Yoshiaki Kuroda, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 4199.

https://doi.org/10.1182/blood.V126.23.4199.4199

Published: 2015

Journal Articles

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Tetsuro Ochi, Taiichi Kyo, MD, Kayo Toishigawa, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Yuta Katayama, Koji Iwato, Hideki Asaoku

Blood (2015) 126 (23): 1594.

https://doi.org/10.1182/blood.V126.23.1594.1594

Published: 2015

Journal Articles

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Taiichi Kyo, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5272.

https://doi.org/10.1182/blood.V124.21.5272.5272

Published: 2014

Journal Articles

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Taiichi Kyo, MD, Kouhei Kyo, MD, Kayo Toishikawa, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Yuta Katayama, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5288.

https://doi.org/10.1182/blood.V124.21.5288.5288

Published: 2014

Journal Articles

Survival of Multiple Myeloma Patients in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD, PhD, Hirokazu Murakami, MD, PhD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Kenshi Suzuki, MD PhD, Atsushi Isoda, MD PhD, Morio Sawamura, MD PhD, Jun Konishi, MD, Kazutaka Sunami, Naoki Takezako, MD PhD, Shotaro Hagiwara, MD PhD, Yoshiaki Kuroda, MD PhD, Takaaki Chou, Eiko Shibata, Kazuyuki Shimizu, MD, Eiichi Nagura, MD

Blood (2014) 124 (21): 5684.

https://doi.org/10.1182/blood.V124.21.5684.5684

Published: 2014

Journal Articles

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Kouhei Kyo, M.D., Mitsuhiro Itagaki, MD, Taiichi Kyo, MD, Takeshi Okatani, M.D., Tetsuro Ochi, Yuta Katayama, MD, PhD, Ryouta Imanaka, M.D., Kouji Iwato, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 3897.

https://doi.org/10.1182/blood.V122.21.3897.3897

Published: 2013

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Treatment Results and Malignant Complications in Patients on Long-Term Treatment with Tyrosine Kinase Inhibitors(TKIs) for Chronic Myeloid Leukemia(CML)

Taiichi Kyo, MD, Kouhei Kyo, M.D., Takesi Okatani, Mitsuhiro Itagaki, M.D., Ryouta Imanaka, M.D., Yuuta Katayama, Kouji Iwato, Hideki Asaoku, MD, Tetsurou Ohti, Megu Ohtaki, Keiko Ohtani

Blood (2012) 120 (21): 3767.

https://doi.org/10.1182/blood.V120.21.3767.3767

Published: 2012

Journal Articles

Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65–70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network

Shuji Ozaki, MD, PhD, Takeshi Harada, MD, Takayuki Saitoh, M.D. Ph.D., Chihiro Shimazaki, MD, PhD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Yoshiaki Kuroda, MD, PhD, Takaaki Chou, MD, PhD, Yumiko Yoshiki, MD, Kenshi Suzuki, MD, PhD, Hirokazu Murakami, M.D., Ph.D., Kunihiko Hayashi, PhD, Antonio Palumbo, MD, Kazuyuki Shimizu, MD

Blood (2012) 120 (21): 5030.

https://doi.org/10.1182/blood.V120.21.5030.5030

Published: 2012

Journal Articles

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Akira Kitanaka, MD, PhD, Akihiro Ihara, MD, PhD, Akira Sakai, MD, PhD, Yoshiaki Kuroda, MD, PhD, Hideki Asaoku, MD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2011) 118 (21): 885.

https://doi.org/10.1182/blood.V118.21.885.885

Published: 2011

Journal Articles

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, M.D., Yuuta Katayama, MD, Koji Iwato, M.D., Hideki Asaoku, MD

Blood (2011) 118 (21): 1503.

https://doi.org/10.1182/blood.V118.21.1503.1503

Published: 2011

Journal Articles

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Taiichi Kyo, MD, Noriaki Yoshida, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Hiromi Yuasa, MD, Koji Iwato, MD, Hideki Asaoku, MD, Yuuta Katayama, MD

Blood (2010) 116 (21): 2934.

https://doi.org/10.1182/blood.V116.21.2934.2934

Published: 2010

Journal Articles

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Taiichi Kyo, MD, Akiko Kimura, MD, Kouhei Kyo, MD, Noriaki Yoshida, MD, Hideki Asaoku, MD, Koji Iwato, MD, Yuuta Katayama, MD, Hiromi Yuasa, MD

Blood (2009) 114 (22): 1052.

https://doi.org/10.1182/blood.V114.22.1052.1052

Published: 2009

Journal Articles

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, MD, Hirotaka Matsui, MD, PhD, Koji Arihiro, MD, PhD, Megumu Fujihara, MD, PhD, Takashi Nishisaka, MD, PhD, Naomi Sasaki, MD, PhD, Yoshito Sadahira, MD, PhD, Akiro Kimura, MD, PhD

Blood (2009) 114 (22): 2927.

https://doi.org/10.1182/blood.V114.22.2927.2927

Published: 2009

Journal Articles

Cytomegalovirus Infection in Patients with Acute Leukemia and MDS.

Hiromi Yuasa, M.D., Ph.D., Taiichi Kyo, MD, Noriaki Yoshida, MD, Yuta Katayama, Hideki Asaoku, MD

Blood (2009) 114 (22): 4167.

https://doi.org/10.1182/blood.V114.22.4167.4167

Published: 2009

Journal Articles

Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy

Blood (2008) 112 (11): 4933.

https://doi.org/10.1182/blood.V112.11.4933.4933

Published: 2008

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Survival of Multiple Myeloma Patients in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Treatment Results and Malignant Complications in Patients on Long-Term Treatment with Tyrosine Kinase Inhibitors(TKIs) for Chronic Myeloid Leukemia(CML)

Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65–70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Cytomegalovirus Infection in Patients with Acute Leukemia and MDS.

Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only